Edgewise Therapeutics, Inc.
EWTX
Clasificación en acciones
#3873
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Precio por acción
$39.70
Última sincronización: 2026-10-21
Capitalización bursátil
$4.27B
Cambio (1 día)
-0.12%
Cambio (1 año)
166.64%
País
US
Comercio Edgewise Therapeutics, Inc. (EWTX)
Categoría
Healthcare
Historial del precio de la acción de Edgewise Therapeutics, Inc. (EWTX)
Precio más alto de cierre: $38.97 el 2026-10-01
Precio más bajo de cierre: $32.43 el 2021-03-01
Precio más bajo de cierre: $32.43 el 2021-03-01
Historial del precio de la acción de Edgewise Therapeutics, Inc. desde 2021 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 38.00% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.29 | -4.16% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
